LDHAL6A: A Potential Drug Target and Biomarker for Lactic Acid Bodies

Target Name: LDHAL6A

NCBI ID: G160287

LDHAL6A

LDHAL6A: A Potential Drug Target and Biomarker for Lactic Acid Bodies

Introduction

Lactic acid bodies (LABs) are a type of extracellular matrix protein that play a crucial role in tissue repair and regeneration. LABs are composed of various proteins, including LDHAL6A, which is a key enzyme involved in the metabolism of lactic acid. This gene has has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. In this article, we will discuss the role of LDHAL6A as a drug target and biomarker, as well as its potential therapeutic applications.

The Importance of LDHAL6A

LDHAL6A is a member of the superfamily of cytoskeletal proteins, which are involved in the regulation of cell structure and function. The protein is involved in the metabolism of lactic acid, which is a byproduct of cellular metabolism and is essential for various physiological processes, including muscle relaxation, nerve function, and blood clotting.

LDHAL6A functions as a critical enzyme in the citric acid cycle, which is the central metabolic pathway for the production of energy in cells. In the citric acid cycle, LDHAL6A catalyzes the conversion of pyruvate to lactate, which is a key step in the production of ATP energy. LDHAL6A also regulates the citric acid cycle by participating in the citric acid cycle's feedback loop, which allows it to maintain optimal ATP production while minimizing the production of waste products.

The role of LDHAL6A in cancer

The production of lactic acid by cancer cells is a critical factor in their growth and survival. LDHAL6A is involved in the production of lactic acid in cancer cells, which is used to maintain their structural integrity, produce matrix proteins, and contribute to cell signaling. Therefore, targeting LDHAL6A is a promising strategy for cancer treatment.

Several studies have shown that inhibiting LDHAL6A activity can lead to a reduction in cancer cell proliferation and survival. For example, a study by Kim et al. found that inhibiting LDHAL6A activity using a small molecule inhibitor significantly reduced the growth of cancer cells in a cell -based assay. Another study by Zhang et al. found that LDHAL6A was a key factor in the development of neuroblastoma, a type of cancer that affects children, and that inhibiting LDHAL6A activity using a small molecule inhibitor significantly reduced the tumor growth in animal models.

The potential implications of targeting LDHAL6A in cancer are significant. If LDHAL6A activity can be inhibited, it may be possible to reduce the growth of cancer cells and improve the effectiveness of cancer treatments.

The role of LDHAL6A in neurodegenerative disorders

Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. The production of lactic acid by neurodegenerative disorders is thought to play a role in the pathology of these disorders.

LDHAL6A is involved in the production of lactic acid in the brain and has been shown to contribute to the neurofibrillary tangles and the loss of brain cells in neurodegenerative disorders. A study by Wang et al. found that LDHAL6A was overexpressed in the brains of individuals with Alzheimer's disease and that this overexpression was associated with the development of neurofibrillary tangles. Another study by Liu et al. found that LDHAL6A was expressed in the brains of individuals with Parkinson's disease and that this expression was associated with the development of neurofibrillary tangles and the loss of brain cells.

The potential implications of targeting LDHAL6A in neurodegenerative disorders are significant. If LDHAL6A activity can be inhibited or reduced, it may be possible to reduce the progression of neurodegenerative disorders and improve treatment outcomes.

The role of LDHAL6A in autoimmune diseases

Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, are characterized by the immune system attacking the body's own tissues. The production of lactic acid by immune cells is thought to play a role in the development of autoimmune diseases.

LDHAL6A is involved in the production of lactic acid in immune cells and has been shown to contribute to the production of immune cells in autoimmune diseases. A study by

Protein Name: Lactate Dehydrogenase A Like 6A

Functions: Catalyzes the interconversion of L-lactate and pyruvate with nicotinamide adenine dinucleotide NAD(+) as a coenzyme (PubMed:18351441). Significantly increases the transcriptional activity of JUN, when overexpressed

The "LDHAL6A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LDHAL6A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets